CHP Sainte Marie Osny

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Head and neck cancer3 trials
• Metastatic breast cancer2 trials
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Recruiting3 trials
• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• UNICANCER3 trials
• Groupe Oncologie Radiotherapie Tete Cou2 trials
• Groupe Oncologie Radiotherapie Tete et Cou1 trial

Running trials

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Recruiting

  Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

  NCT07264075· Phase 3· Groupe Oncologie Radiotherapie Tete et Cou· Source

• Recruiting

  Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

  NCT06450314· Phase 2· UNICANCER· Source

• Active, not recruiting

  Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck

  2024-513206-65-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source

• Active, not recruiting

  A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse

  NCT01952223· Phase 3· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer2 recruiting
• Head and neck cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.

  2022-502584-38-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source